Form 4: Sonnet BioTherapeutics Director Lori McNeill Reports Significant RSU Grant

Sonnet BioTherapeutics Holdings, Inc. Director Lori McNeill reported the acquisition of 4,000 restricted stock units, increasing her beneficial ownership to 4,394 shares, as detailed in a recent Form 4 filing.

Summary

• Lori McNeill, a Director of Sonnet BioTherapeutics Holdings, Inc. (SONN), filed a Form 4 statement regarding changes in beneficial ownership.
• On July 11, 2025, Lori McNeill was granted 4,000 restricted stock units (RSUs) by the Issuer.
• These restricted stock units will be settled in shares of Sonnet BioTherapeutics' common stock, par value $0.0001.
• The 4,000 restricted stock units are scheduled to vest 100% on the earlier of January 8, 2026, or the date of a 'Change in Control' as defined under the Issuer's 2020 Omnibus Equity Incentive Plan.
• Following this transaction, Lori McNeill's total beneficial ownership in Sonnet BioTherapeutics stands at 4,394 shares, which includes these newly granted unvested restricted stock units.
• All reported share amounts reflect the company's 1:22 reverse stock split effective as of August 31, 2023, and a subsequent 1:8 reverse stock split effective as of September 30, 2024.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive signal of alignment between management and shareholder interests, although it is a routine compensation event and not indicative of extraordinary performance.

Positives

• A Director, Lori McNeill, was granted 4,000 restricted stock units, which aligns her interests with those of the company's shareholders.

Future Outlook

The 4,000 restricted stock units granted to Director Lori McNeill are scheduled to vest 100% on the earlier of January 8, 2026, or a Change in Control event, indicating a future increase in her vested equity holdings.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically an equity grant, which is a common component of executive and director compensation packages across various industries, particularly in biotechnology where long-term incentives are used to align interests with company performance.

Related Party Transactions

• Grant of 4,000 restricted stock units to Director Lori McNeill as part of the Issuer's 2020 Omnibus Equity Incentive Plan.

Stakeholder Impact

• Shareholders: The grant of restricted stock units to a director enhances the alignment of management's financial interests with those of the shareholders, potentially fostering long-term value creation.

Next Steps

• Vesting of 4,000 restricted stock units on the earlier of January 8, 2026, or a Change in Control event.

Key Dates

Recommendation

Keywords

Sonnet BioTherapeutics, SONN, Form 4, insider transaction, beneficial ownership, restricted stock units, RSU, director, equity grant, stock split